Exom starts an observational prospective multicenter study to assess the long-term effectiveness and tolerability of a new  PCSK9-I inhibitor in the real life clinical practice, in a severe hypercholesterolemic population resistant to full dosage statins.
The study will last for about six year and will enroll 800 patients from 40 selected hospitals.
The most advanced digital solutions will be implemented for the conduction and oversight of this trial, from the eFeasibility to the eTMF and electronic Informed Consent. Moreover the risk for the occurrence of quality and safety issues will be regularly and centrally monitored through the use of  the “Risk Based Monitoring platform, Genius RIBAM™.

Share This

Exom is now Kapadi

 

Once three entities – OncoBay Clinical, Clinscience, and Exom Group s.r.l – now we stand as one, bringing forth a symphony of expertise and seamless operations. To celebrate our unity, we re-brand under the banner of Kapadi, and embark on a new chapter of exceptional service in oncology clinical research.

Kapadi is not just a name; it's a testament to our fusion. It signifies the our standing as a global CRO powerhouse committed to accelerating groundbreaking cancer therapies that uplift patients worldwide. From conceptualizing studies, navigating regulations, and analyzing data, we provide a comprehensive array of services designed to empower your oncology clinical trials.

Visit Kapadi.com